• Customer Care
  • (888) 123-4567

PROCESS DEVELOPMENT SCIENTIST

Rise Therapeutics is recruiting a full-time process development scientist with a background in bacterial fermentation to work in our Rockville, Maryland laboratory. This position offers a unique opportunity for entrepreneurial minded scientists to advance skills and experience necessary for a successful career in the biotechnology industry. The process development scientist will support product development strategies to create new and innovative medicines.

 Required Qualifications

  • Degree (MS and/or PhD) in the life sciences or biomedical engineering
  • Background in bacterial fermentation with experience operating small scale (1-10L) bioreactors
  • Familiarity with good manufacturing practices (GMP)
  • Effective communication skills
  • Ability to contribute in a fast-paced, highly dynamic environment
  • Strong sense of responsibility for deadlines and data accuracy
  • Rigor and attention to detail in all aspects of science
  • Comfort with collaboration in a team-based environment

 

Duties and Responsibilities

  • Establishing control loops to monitor/maintain DO, pH, and other parameters for Gram+ bacterial fermentation
  • Lead projects developing, optimizing, advancing, and scaling fermentation processes
  • Set and execute strategic direction for process development and manufacturing

Benefits

  • Support initiatives to develop new treatments for autoimmunity, infection, and cancer
  • Gain experience working in biotech
  • Mentorship from seasoned research entrepreneurs and business executives
  • Expand relationships/connections with leading biotechnology researchers

 

About Rise Therapeutics

Rise Therapeutics is an emerging, privately held biotech company located in Rockville, Maryland, which develops novel synthetic biology-based medicines. As a product focused company, we leverage our proprietary drug delivery platform and GMP manufacturing infrastructure to create targeted immunologically-directed Live Biotherapeutic Products (LBPs). Rise harnesses novel discoveries in microbiome biology as it relates to regulation of immune function to identify new immune regulatory pathways and develop unique, first-in-class immune modulatory drugs for the treatment of autoimmunity, inflammation, infection, and cancer. For more information, please visit our website at www.risetherapeutics.com

 

Please email your CV or resume to: This email address is being protected from spambots. You need JavaScript enabled to view it.

Title document as "last name first inital-PrDScientist-resume.pdf" e.g. "DoeJ-PrDScientist-resume.pdf"

Our News

Biotech company receives follow-on funding to accelerate ongoing clinical development efforts

TEDCO, Maryland’s economic engine for technology companies, announced a recent Seed Funds investment of $200,000 into Rise Therapeutics, a Maryland-based biotechnology company. TEDCO’s Seed Funds invest in early-stage, technology and life sciences companies and provides access to gap financing.

 

Rockville, Maryland - Rise Therapeutics, a biotech company focused on developing novel immunological-directed synthetic biology-based therapeutics, announced today that it has received funding from the National Institutes of Health (NIH) to develop a novel therapeutic for Acute Respiratory Distress Syndrome (ARDS). The funding will support completion of product validation studies and preparation for clinical development for the program. Rise’s functionally directed immunotherapy engages natural gut microbiome-associated immunological processes with the potential to diminish lung neutrophilia, reduce inflammation, upregulate regulatory T cells, and restore airways epithelial barrier to balance and reset the patient’s immunological repertoire.

Rockville, Maryland, January 31st, 2023 – Rise Therapeutics, a biopharmaceutical company engaged in developing novel oral synthetic biology medicines, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a Phase 1 clinical trial of its lead program candidate, R-3750.